Pappas Capital LLC
04/03/2007 | Press release | Archived content
Syndax Pharmaceuticals closes $40 Million Series A Financing
News | 04. 03. 2007
Syndax, a privately-held biopharmaceutical company focused on developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens, announced today the closing of a $40 million Series A financing. Syndax was co-founded by Eckard Weber, M.D., Domain Associates, and Ronald Evans, Ph.D, Salk Institute for Biological Studies and Howard Hughes Medical Institute. The financing was co- led by Domain Associates and MPM Capital. Co-investors include Avalon Ventures, Forward Ventures, and Pappas Ventures. The proceeds of the Series A will be used to fund development of a clinical pipeline.
Pappas Capital LLC published this content on April 03, 2007, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:11 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]